Views: 1,248 | Downloads:
21
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
The Metabolic and Bone Density Effects of Continuous Combined 17-beta Estradiol and Noresthisterone Acetate Treatments in Thai Postmenopausal Women : A Double-Blind Placebo-Controlled Trial
Bunyavejchevin S 
,
Limpaphayom KK
,
Limpaphayom KK Objective:
To compare the changes of lipid parameters, liver function tests, fasting
plasma glucose and bone density in Thai postmenopausal women who received this combined
hormonal treatment and placebo.
Study design:
Double-blinded, randomized controlled trial study.
Material and Method:
Sixty postmenopausal women attending the menopause clinic at
Chulalongkorn Hospital from July, 1996 to December, 1996, were enrolled in the study. The
patients were randomized to receive the placebo or drug (17 beta-estradiol 2 mg and norethisterone
acetate 1 mg) continuously. Patient characteristics, physical examination, liver function tests,
fasting plasma glucose, lipid parameters (fasting total cholesterol, low density lipoprotein
cholesterol (LDL), high density lipoprotein (HDL) and triglyceride level) and bone densitometry
were performed before beginning the study. The lipid parameters were repeated at 3, 6 and 12
months. Fasting plasma glucose, liver function tests and bone densitometry were repeated at 12
months.
Results:
In the drug group, there were significant changes in the cholesterol at 3, 6
and 12 months when compared to the baseline. There were significant differences at 3, 6 and 12
months when compared between groups. The HDL values were not significantly different
within groups. The LDL values at 3, 6, 12 months were significantly lower than the baseline in the
drug group when compared within groups and at 6, 12 months in the placebo group. The trigly-
ceride values were not significantly different between groups and within groups. There was no
significant change between groups and within groups of fasting plasma glucose, total bilirubin,
direct bilirubin, AST, AL T, albumin and globulin. The alkaline phosphatase values were sig-
nificantly decreased at 12 months in the drug group. The bone density of total BMD and T-score
at the spine of the drug group increased significantly at 12 months. The per cent change per year
was +5.1. In contrast, the values in the placebo group decreased significantly, the per cent change
per year was -0.9. The same pattern was also found in the bone density of the total hip. But when
focused to the femoral neck, we found no significant change in both groups.
*Department of Obstetrics and Gynaecology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
46
To compare the changes of lipid parameters, liver function tests, fasting
plasma glucose and bone density in Thai postmenopausal women who received this combined
hormonal treatment and placebo.
Study design:
Double-blinded, randomized controlled trial study.
Material and Method:
Sixty postmenopausal women attending the menopause clinic at
Chulalongkorn Hospital from July, 1996 to December, 1996, were enrolled in the study. The
patients were randomized to receive the placebo or drug (17 beta-estradiol 2 mg and norethisterone
acetate 1 mg) continuously. Patient characteristics, physical examination, liver function tests,
fasting plasma glucose, lipid parameters (fasting total cholesterol, low density lipoprotein
cholesterol (LDL), high density lipoprotein (HDL) and triglyceride level) and bone densitometry
were performed before beginning the study. The lipid parameters were repeated at 3, 6 and 12
months. Fasting plasma glucose, liver function tests and bone densitometry were repeated at 12
months.
Results:
In the drug group, there were significant changes in the cholesterol at 3, 6
and 12 months when compared to the baseline. There were significant differences at 3, 6 and 12
months when compared between groups. The HDL values were not significantly different
within groups. The LDL values at 3, 6, 12 months were significantly lower than the baseline in the
drug group when compared within groups and at 6, 12 months in the placebo group. The trigly-
ceride values were not significantly different between groups and within groups. There was no
significant change between groups and within groups of fasting plasma glucose, total bilirubin,
direct bilirubin, AST, AL T, albumin and globulin. The alkaline phosphatase values were sig-
nificantly decreased at 12 months in the drug group. The bone density of total BMD and T-score
at the spine of the drug group increased significantly at 12 months. The per cent change per year
was +5.1. In contrast, the values in the placebo group decreased significantly, the per cent change
per year was -0.9. The same pattern was also found in the bone density of the total hip. But when
focused to the femoral neck, we found no significant change in both groups.
*Department of Obstetrics and Gynaecology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
46
Download:
PDF